CMR Surgical is a technology company.
CMR Surgical has raised $1.1B across 6 funding rounds.
CMR Surgical has raised $1.1B in total across 6 funding rounds.
CMR Surgical has raised $1.1B in total across 6 funding rounds.
CMR Surgical's investors include Cambridge Innovation Capital, Forbion, Sofinnova Investments, TotalEnergies Ventures.
CMR Surgical is a British medical technology company founded in 2014 and headquartered in Cambridge, UK, specializing in surgical robotics. It develops the Versius system—a compact, portable, and modular next-generation robotic platform designed for minimal access surgery (MAS), also known as keyhole surgery, across specialties like gynaecology, general surgery, thoracic surgery, urology, and colorectal surgery[1][2][6]. Versius serves hospitals and surgeons worldwide, addressing the limitations of conventional robotic systems by enabling better dexterity, precision, 3D HD visualization, and seamless integration into busy operating rooms, while improving patient outcomes through reduced invasiveness and offering value via innovative pricing models[1][3][5]. The company has achieved unicorn status in 2019, raised over $765 million in funding (including a record $600 million Series D in 2021), completed over 5,000 procedures globally, and expanded to more than 20 markets across Europe, Asia-Pacific, Latin America, the Middle East, Africa, and Australia[1][2][4][6].
CMR Surgical, originally named Cambridge Medical Robotics, was founded in 2014 by a team of engineers and clinicians in Cambridge, UK, with the vision to make high-quality keyhole surgery accessible globally[1][6]. The idea emerged from recognizing the drawbacks of existing bulky, expensive surgical robots like da Vinci, prompting the development of Versius—a system engineered for versatility, portability, and affordability while meeting clinical standards[1][2]. Early traction came quickly: by 2020, Versius had performed over 1,000 procedures, including in the UK's NHS, and secured regulatory approvals in multiple regions; venture backing from firms like CIC through Series A to C fueled unicorn status in 2019[2][6]. Pivotal moments include the 2021 $600 million Series D—the largest private medtech round ever—and ongoing expansions like FDA 510(k) clearance for Versius Plus in cholecystectomy in the US, plus a new UK manufacturing facility in 2023 capable of 500 systems annually[1][3][6].
CMR Surgical rides the explosive growth of surgical robotics, a market projected to expand as MAS demands rise amid aging populations, rising chronic diseases, and post-pandemic emphasis on minimally invasive procedures that shorten recovery and cut costs[1][4]. Timing is ideal: while incumbents dominate premium segments, CMR's focus on modularity and portability democratizes access in underpenetrated regions like Asia-Pacific and Latin America, where over 20 markets now host Versius[4][6]. Favorable forces include regulatory wins (e.g., US FDA clearance), falling tech costs, and data analytics trends enabling evidence-based surgery; CMR influences the ecosystem by challenging high-cost models, fostering surgeon-hospital partnerships, and building a software-driven platform for continuous innovation[2][3][4].
CMR Surgical is primed for accelerated global scale, with Versius Plus expansions into soft tissue procedures, new imaging tech, and manufacturing ramp-up signaling 2025-2027 growth in the US and emerging markets[3][5][6]. Trends like AI-enhanced robotics, real-time data registries, and hybrid pricing will shape its path, potentially capturing share from legacy players by prioritizing accessibility. Its influence may evolve from disruptor to standard-setter, empowering more surgeons to deliver keyhole surgery worldwide and tying back to its founding mission of transforming care for all patients in need[1][4].
CMR Surgical has raised $1.1B across 6 funding rounds. Most recently, it raised $160.0M Series D in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $160.0M Series D | Cambridge Innovation Capital, Forbion, Sofinnova Investments | |
| Jun 1, 2021 | $590.0M Series D | Cambridge Innovation Capital, Forbion, Sofinnova Investments | |
| Sep 1, 2019 | $240.0M Series C | Cambridge Innovation Capital, Forbion, Sofinnova Investments | |
| Jun 1, 2018 | $99.0M Series B | Cambridge Innovation Capital, Forbion, Sofinnova Investments | |
| Sep 1, 2017 | $26.0M Series A | Cambridge Innovation Capital, Forbion, Sofinnova Investments | |
| Jul 1, 2016 | $20.0M Series A | Cambridge Innovation Capital, Forbion, Sofinnova Investments, TotalEnergies Ventures |